TeeMan123
Posted - 2 days ago
$FOLD sell.. the... company...
USDollar
Posted - 3 days ago
$FOLD any knowledge about Dec - 11strike 5557 puts pls.
ErmiaJi
Posted - 6 days ago
😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $PRGO $FOLD
Greatguns
Posted - 1 week ago
$FOLD JP Morgan Maintains Overweight on Amicus Therapeutics, Raises Price Target to $17
Thestocktraderhubzee
Posted - 1 week ago
WATCHLIST NOV 13 2024..
$GTN Guggenheim Maintains Buy on Gray Television, Lowers Price Target to $8
$BRDG TD Cowen Maintains Hold on Bridge Investment Group, Lowers Price Target to $10
$AGEN HC Wainwright & Co. Maintains Neutral on Agenus, Lowers Price Target to $7
$BAP JP Morgan Maintains Overweight on Credicorp, Raises Price Target to $219
$FOLD JP Morgan Maintains Overweight on Amicus Therapeutics, Raises Price Target to $17
Doozio
Posted - 1 week ago
$VKTX some ⏰ YO must $fold
Phjamt
Posted - 2 weeks ago
$FOLD Despite the narrative of the reason behind the drop, I am an early 🐦 in this.
Grant_51
Posted - 2 weeks ago
$FOLD Was curious about the bearish drops here despite strong financials, so I dug a bit into the Aurobindo case. Galafolds New drug exclusivity is up in August of next year. Amicus still has the patent to protect against new entries as we saw with Teva settlement allowing generics in 2037.. At a glance, this appears to be a straightforward infringement, but the fact it has been ongoing for two years is a bit baffling....
Grant_51
Posted - 2 weeks ago
$FOLD Summary of Major Points:
Pros:
1. Total quarterly revenue of $142 million, up 37% year-over-year.
2. The company raised its revenue guidance for Galafoldto 16%-18%.
3. Pombiliti and Opfolda - higher patient starts thanpreviously expected.
4. Reduced non-GAAP operating expenses
5. Recent settlement with Teva
6. Geography Expansion: regulatory submissions for new regions continue.
Cons:
1. Lawsuit with Aurobindo Ongoing. No comments made as it is active with litigation.
2. Lower margins in 2025 due to usage of all previously capitalized inventory. Dropping from 90's to mid 80's.
3. No near future (~12 month) pipeline development.- From Q&A, not really a con but it wasn't a positive just something to call out...
Once the litigation wraps with Aurobindo if all goes similar to Teva I'd expect this back in the 12's or 13's.
All4Retiring
Posted - 2 weeks ago
$FOLD PerceptiveAdvisers please find a buyer for $FOLD
valueforme
Posted - 2 weeks ago
$FOLD Nothing in the press release warrants -5% reaction. Crazy. I sold around 12 after the patent news pop, but tempting to buy back
Grant_51
Posted - 2 weeks ago
$FOLD and ideas on what from the call is leading to the dip? Haven't listened to the call myself yet, will this afternoon
OpenOutcrier
Posted - 2 weeks ago
$FOLD (+8.6% pre) Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates - GN https://ooc.bz/l/47031
Doozio
Posted - 2 weeks ago
🐑 $fold beFOUR POWL n rates. They get SKWD goin INTA eps with their huckleberries in da FUTUre of 🧠⏰ n they don’t PAY $aten tion $ttwo whuts NEXN. 🧠⏰♾️
BPharmCatalyst
Posted - 2 weeks ago
$TNGX is prioritizing TNG462, a promising PRMT5 inhibitor in NSCLC and pancreatic cancer, with combination studies planned for 1H 2025, while halting glioblastoma-focused TNG908. The company holds $293.3M in cash, funding operations into Q3 2026. Q3 2024 saw collaboration revenue grow to $11.6M and a net loss of $29.2M ($0.27/share) due to rising R&D expenses. See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2024/tango-tngx-earnings-pipeline-priorities-evotec-evo-earnings $EVO $MGNX $GLYC $FOLD
PDM5
Posted - 2 weeks ago
$FOLD boom. Someone buy us Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year
Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year
Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024
Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER
Reducing non-GAAP Operating Expense Guidance to $340M to $350M
TeeMan123
Posted - 2 weeks ago
$FOLD earnings are off the charts amazing 🤩
Doozio
Posted - 2 weeks ago
da fook they gonna say in da FUTUre of 🧠⏰ wen $FOLD becomes raise wen yo PAY $aten NEXN with $ea goin $$$ pattern during 🧠⏰♾️
Doozio
Posted - 2 weeks ago
$RVLV there are no coincidence as 2mro in da FUTUre of 🧠⏰ they shall say no $fold INTA 🧠⏰♾️
insiderbuyingselling
Posted - 2 weeks ago
$FOLD new insider selling: 7500 shares. http://insiderbuyingselling.com/?t=FOLD
Stocksrunner
Posted - 2 weeks ago
Amicus Therapeutics $FOLD recently gained 8.2%, with Wall Street eyeing a 51.09% upside.
Doozio
Posted - 2 weeks ago
Who wud $fold INTA 🧠⏰♾️?
Doozio
Posted - 2 weeks ago
$EA yes they are. Bahhht that was the end of a cycle when they told YO to $fold. Da fook they gonna say NEXN week? N all YO gotta do is PAY $aten tion n wUtch during 🧠⏰♾️
Doozio
Posted - 3 weeks ago
Da FUTUre of 🧠⏰ is NOW INTA NEXN week wen NO $fold shud get obvious during 🧠⏰♾️
biotech
Posted - 10/29/24
$FOLD Galafold® Q2 Revenue of $110.8M, up 17% Year-over-Year say $500M per year $SNY Fabrazyme Q1 sales increased by 7.7% to €253 million say $1B per year Patients want and need #IsaCiv $SGMO will steal most of this on day 1 on the market
swingingtech
Posted - 10/29/24
$HLF $FOLD $RH
https://wallstreetwaves.com/significant-monday-options-trading-insights-hlf-fold-rh/
swingingtech
Posted - 10/24/24
$FOLD $CLPR $HROW
https://wallstreetwaves.com/best-momentum-stocks-to-buy-for-october-24th/
swingingtech
Posted - 1 month ago
$FOLD
https://wallstreetwaves.com/intriguing-fold-put-options-set-for-december-20th/
